Puma Biotechnology announces presentation of findings from a phase II study of alisertib in… BusinessWire Jun 3, 2024 Ongoing biomarker analysis may help clarify which patients could benefit most from alisertib Puma Biotechnology, announced the…
Mylan and Biocon to present phase-III trastuzumab biosimilar data at ASCO annual meeting Usha Sharma Jun 6, 2016 HERITAGE study shows comparable efficacy, safety and immunogenicity to branded trastuzumab in HER2-positive metastatic breast…
